| Autor: |
Yasuhiro Nakamura, Kenjiro Namikawa, Yukiko Kiniwa, Hiroshi Kato, Osamu Yamasaki, Shusuke Yoshikawa, Takeo Maekawa, Shigeto Matsushita, Tatsuya Takenouchi, Takashi Inozume, Yasuo Nakai, Satoshi Fukushima, Shintaro Saito, Atsushi Otsuka, Noriki Fujimoto, Taiki Isei, Natsuki Baba, Taisuke Matsuya, Ryo Tanaka, Takahide Kaneko, Masazumi Onishi, Yutaka Kuwatsuka, Kotaro Nagase, Takehiro Onuma, Motoo Nomura, Yoshiyasu Umeda, Naoya Yamazaki |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
European Journal of Cancer. 176:78-87 |
| ISSN: |
0959-8049 |
| Popis: |
Although anti-PD-1 antibody monotherapy (PD-1) is commonly used to treat advanced acral melanoma (AM), its efficacy is limited. Further, data on the efficacy of PD-1 plus anti-CTLA-4 antibody (PD-1+CTLA-4) for the treatment of AM are limited. Therefore, we compared the efficacy of PD-1+CTLA-4 and PD-1 in the treatment of Japanese patients with advanced AM.This retrospective study evaluated patients with advanced AM who were treated with PD-1 or PD-1+CTLA-4 as first-line immunotherapy in 24 Japanese institutions between 2014 and 2020. Treatment efficacy focussing on the objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) was compared between the two groups.In total, 254 patients (palm and sole melanoma [PSM], n = 180; nail apparatus melanoma [NAM], n = 74) were included. Among the patients with PSM, the ORR (19% vs. 31%; P = 0.44), PFS (5.9 vs. 3.2 months; P = 0.74), and OS (23.1 vs. not reached; P = 0.55) did not differ significantly between the PD-1 and PD-1+CTLA-4 groups. Among the patients with NAM, the ORR (61% vs. 10%; P 0.001) was significantly higher and PFS was longer (6.4 vs. 3.8 months; P = 0.10) in the PD-1+CTLA-4 group than in the PD-1 group. Cox multivariate analysis demonstrated that PD-1+CTLA-4 is an independent predictor of a favourable PFS in patients with NAM (P = 0.002).The efficacy of PD-1+CTLA-4 is not superior to that of PD-1 for the treatment of advanced PSM. However, PD-1+CTLA-4 may be more efficacious than PD-1 for the treatment of advanced NAM. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect